China Shineway Pharmaceutical Group Limited
CSWYF
$0.9398
$0.07378.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -19.84% | -19.20% | -15.82% | -17.10% | -2.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.84% | -19.20% | -15.82% | -17.10% | -2.39% |
| Cost of Revenue | -17.87% | -17.22% | -16.29% | -17.55% | -0.50% |
| Gross Profit | -20.49% | -19.86% | -15.67% | -16.94% | -3.01% |
| SG&A Expenses | -18.53% | -17.88% | -20.02% | -21.23% | -2.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.03% | -17.37% | -18.53% | -19.77% | -3.26% |
| Operating Income | -28.03% | -27.45% | -7.44% | -8.84% | 1.71% |
| Income Before Tax | -49.96% | -49.56% | 24.27% | 22.39% | 10.75% |
| Income Tax Expenses | -22.65% | -22.03% | 26.78% | 24.86% | -21.49% |
| Earnings from Continuing Operations | -55.16% | -54.80% | 23.35% | 21.48% | 20.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.16% | -54.80% | 23.35% | 21.48% | 20.13% |
| EBIT | -28.03% | -27.45% | -7.44% | -8.84% | 1.71% |
| EBITDA | -34.41% | -30.03% | -7.68% | -9.08% | 0.91% |
| EPS Basic | -55.02% | -54.92% | 23.49% | 21.68% | 20.00% |
| Normalized Basic EPS | -50.76% | -50.61% | 24.18% | 22.41% | 11.22% |
| EPS Diluted | -55.25% | -54.92% | 23.49% | 21.68% | 20.00% |
| Normalized Diluted EPS | -50.76% | -50.61% | 24.18% | 22.41% | 11.22% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | 24.33% | 22.48% | -- |
| Payout Ratio | 1.24% | 1.24% | 0.09% | 0.09% | -0.18% |